A study of 17,604 people aged 45 and over found that semaglutide, the active ingredient in Wegovy and Ozempic, reduced the risk of major cardiac events by 20 percent regardless of participants' starting weight or amount of weight lost during treatment.</span

The New York Times

The Telegraph

A study of 17,604 people aged 45 and over found that semaglutide, the active ingredient in Wegovy and Ozempic, reduced the risk of major cardiac events by 20 percent regardless of participants' starting weight or amount of weight lost during treatment.

Researchers discovered that people with a BMI of 27, which represents the average for UK adults and classifies them as overweight but not obese, experienced similar cardiovascular benefits as those with the highest BMI scores in the severely obese category.</span

Daily Mirror

The Times

Researchers discovered that people with a BMI of 27, which represents the average for UK adults and classifies them as overweight but not obese, experienced similar cardiovascular benefits as those with the highest BMI scores in the severely obese category.

The study found that shrinking waist circumference accounted for approximately one-third of semaglutide's cardiovascular benefits, while the remaining two-thirds of the heart health improvements remain unexplained by current medical understanding.</span

Guardian

EuroNews

The study found that shrinking waist circumference accounted for approximately one-third of semaglutide's cardiovascular benefits, while the remaining two-thirds of the heart health improvements remain unexplained by current medical understanding.

Professor John Deanfield from University College London stated that abdominal fat poses greater cardiovascular risks than overall weight, explaining why waist size reduction showed stronger correlation with heart benefits than total weight loss.</span

Independent

The Sun

Professor John Deanfield from University College London stated that abdominal fat poses greater cardiovascular risks than overall weight, explaining why waist size reduction showed stronger correlation with heart benefits than total weight loss.

The research suggests that cardiovascular benefits from semaglutide begin appearing within the first 20 weeks of treatment, before significant weight loss occurs, indicating the drug has direct effects on heart disease beyond weight reduction mechanisms.</span

Mirage News

The research suggests that cardiovascular benefits from semaglutide begin appearing within the first 20 weeks of treatment, before significant weight loss occurs, indicating the drug has direct effects on heart disease beyond weight reduction mechanisms.

The NHS currently limits access to weight loss injections to 240,000 people with highest need over three years, while experts suggest the findings support broadening access beyond strict BMI restrictions for cardiovascular disease prevention.</span

Daily Mail

The NHS currently limits access to weight loss injections to 240,000 people with highest need over three years, while experts suggest the findings support broadening access beyond strict BMI restrictions for cardiovascular disease prevention.

Ozempic Cuts Heart Disease Risk 20% Regardless of Weight Loss

Sign Up for Our Free Newsletters
Sign Up for Our Free Newsletters

Ozempic Cuts Heart Disease Risk 20% Regardless of Weight Loss

Sign Up for Our Free NewslettersSign Up for Our Free Newsletters

Sign Up for Our Free Newsletters
Sign Up for Our Free Newsletters